Published in Am J Med on December 01, 2003
Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis (2011) 3.63
Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis (2007) 3.16
Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis (2007) 2.37
Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS (2007) 2.24
Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med (2013) 2.16
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend (2010) 1.67
Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr (2007) 1.61
Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav (2012) 1.38
How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART? HIV Clin Trials (2008) 1.25
A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. Drug Alcohol Depend (2011) 1.19
Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses (2010) 1.08
Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep (2007) 1.05
Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J (2005) 1.02
Computational modeling and multilevel cancer control interventions. J Natl Cancer Inst Monogr (2012) 1.02
Incorporating quality of evidence into decision analytic modeling. Ann Intern Med (2007) 1.01
A comparison of HAART outcomes between the US military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS). PLoS One (2013) 1.00
Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV. Drug Alcohol Depend (2008) 0.96
Optimal investment in HIV prevention programs: more is not always better. Health Care Manag Sci (2009) 0.96
A cost analysis of an Internet-based medication adherence intervention for people living with HIV. J Acquir Immune Defic Syndr (2012) 0.92
The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy (2008) 0.92
The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Med Decis Making (2008) 0.87
Cost effectiveness of a computer-delivered intervention to improve HIV medication adherence. BMC Med Inform Decis Mak (2013) 0.86
Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value? Value Health (2010) 0.85
A qualitative examination of the indirect effects of modified directly observed therapy on health behaviors other than adherence. AIDS Patient Care STDS (2008) 0.80
Cost of behavioral interventions utilizing electronic drug monitoring for antiretroviral therapy adherence. J Acquir Immune Defic Syndr (2013) 0.79
Directly administered antiretroviral therapy for HIV-infected individuals in opioid treatment programs: results from a randomized clinical trial. PLoS One (2013) 0.79
Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs. BMC Infect Dis (2011) 0.78
The economic viability of antiretroviral adherence interventions. Am J Med (2003) 0.77
Exploring ART intake scenes in a human rights-based intervention to improve adherence: a randomized controlled trial. AIDS Behav (2013) 0.77
Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients. Drug Saf (2016) 0.76
Commentary: demonstrating cost-effectiveness in pediatric psychology. J Pediatr Psychol (2014) 0.75
Cost-effectiveness of a nurse-based intervention (AIMS) to improve adherence among HIV-infected patients: design of a multi-centre randomised controlled trial. BMC Health Serv Res (2013) 0.75
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med (2006) 3.09
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96
Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med (2008) 2.74